
## **Tomas Forslund**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3354073/publications.pdf Version: 2024-02-01



TOMAS FORSLUND

#	Article	IF	CITATIONS
1	Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. European Journal of Clinical Pharmacology, 2016, 72, 329-338.	1.9	103
2	Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: Experience from the Stockholm health care system. International Journal of Cardiology, 2013, 170, 208-214.	1.7	69
3	Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non–Vitamin K Antagonist Oral Anticoagulants. Stroke, 2018, 49, 2122-2128.	2.0	56
4	Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace, 2018, 20, 420-428.	1.7	46
5	Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA2DS2VASc scores: experience from the Stockholm region. European Journal of Clinical Pharmacology, 2014, 70, 1477-1485.	1.9	44
6	Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. British Journal of Clinical Pharmacology, 2017, 83, 642-652.	2.4	39
7	Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f72-f80.	3.0	37
8	Trends in psychiatric diagnoses, medications and psychological therapies in a large Swedish region: a population-based study. BMC Psychiatry, 2020, 20, 328.	2.6	30
9	Patterns of multimorbidity and pharmacotherapy: a total population cross-sectional study. Family Practice, 2021, 38, 132-139.	1.9	28
10	Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non–Vitamin K Oral Anticoagulants. American Journal of Cardiology, 2017, 120, 1302-1308.	1.6	24
11	Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace, 2021, 23, 1722-1730.	1.7	24
12	Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. European Heart Journal, 2022, 43, 3528-3538.	2.2	22
13	Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 3-10.	3.0	15
14	Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. European Journal of Clinical Pharmacology, 2017, 73, 1315-1322.	1.9	14
15	Venous thromboembolism 2011–2018 in Stockholm: a demographic study. Journal of Thrombosis and Thrombolysis, 2019, 48, 668-673.	2.1	13
16	Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding. Clinical Pharmacology and Therapeutics, 2020, 107, 287-294.	4.7	10
17	Greedy caliper propensity score matching can yield variable estimates of the treatmentâ€outcome association—A simulation study. Pharmacoepidemiology and Drug Safety, 2021, 30, 934-951.	1.9	9
18	Early Risk of Stroke in Patients Undergoing Acute Versus Elective Cardioversion for Atrial Fibrillation. Journal of the American Heart Association, 2021, 10, e021716.	3.7	1

#	Article	IF	CITATIONS
19	Abstract 13898: Atrial Fibrillation And Persistence With Anticoagulant Treatment. Circulation, 2015, 132, .	1.6	0